Markets Insider · 25 Oct 2026, 22:35 UTCBeOne Medicines presents new data across solid tumor disease areas at ESMO 2026BeOne Medicines8.8% of KURE
South China Morning Post · 26 Oct 2026, 13:04 UTCChinese biotech giant WuXi AppTec raises 2026 outlook after profit surgeWuXi AppTec5.8% of KURE
Markets Insider · 25 Oct 2026, 22:20 UTCInnovent Biologics presents Phase 2 data for IBI354 at ESMO CongressInnovent Biologics8.8% of KURE
The Manila times · 27 Oct 2026, 12:07 UTCLegend Biotech to Host Investor Conference Call on Third Quarter 2026 ResultsLegend Biotech1.3% of KURE
Markets Insider · 25 Oct 2026, 22:15 UTCAkeso announces Phase III HARMONi-GI1 trial met its primary endpointAkeso3.7% of KURE
wallstreet:online · 25 Oct 2026, 15:52 UTCIvonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in ChinaAkeso3.7% of KURE
The Manila times · 24 Oct 2026, 02:24 UTCLunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology DevelopmentAkeso3.7% of KURE
